Generated: April 25, 2017
|Title:||Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy|
|Abstract:||Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.|
|Inventor(s):||Cook; Harry (Eden Prairie, MN), Hamilton; Martha (St. Paul, MN), Danielson; Douglas (Otsego, MI), Goderstad; Colette (St. Paul, MN), Reardan; Dayton (Excelsior, MN)|
|Assignee:||Jazz Pharmaceuticals, Inc. (Palo Alto, CA)|
1. A method of treating a condition responsive to sodium gamma-hydroxybutyrate, comprising orally administering to a patient afflicted with the condition an aqueous
composition comprising a first dose of about 4.5 to about 10 grams of sodium gamma-hydroxybutyrate within an hour prior to initial sleep onset and an aqueous composition comprising a second dose of about 4.5 to about 10 grams within 2 to 5 hours
following initial sleep onset, wherein the aqueous composition of the first dose and the aqueous composition of the second dose each comprises a respective concentration of sodium gamma-hydroxybutyrate of greater than about 500 mg/mL, wherein the
condition is selected from the group consisting of apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.
2. The method of claim 1, wherein the condition is narcolepsy.
3. The method of claim 1, wherein the condition is a catalepsy.